Chronic Migraine — Preventive Therapies & CGRP

Key Points

• Chronic migraine is defined by headache on at least 15 days per month for more than three months, with migraine features on at least eight days per month.
• Use a headache diary to document frequency, migraine days, acute-medication use, disability, menstrual relationship, sleep, caffeine, triggers, and response to therapy.
• Offer preventive therapy when attacks are frequent or disabling.
• Use Headache diary and other targeted evaluation to answer specific diagnostic or safety questions rather than ordering broad testing without a plan.
• Escalate urgently for thunderclap headache, meningismus, fever, papilledema, focal deficit, seizure, or altered mental status.
• Other major warning findings include new headache in pregnancy/postpartum, cancer, immunocompromise, or age over 50 with concerning features and progressive pattern change or failure to improve despite appropriate migraine therapy where the diagnosis may be wrong.
• Medication and procedural choices should be matched to physiology, contraindications, renal/hepatic function, pregnancy status, and interaction risk when relevant.
• Track monthly migraine days and disability rather than asking only whether headaches are 'better.' Give a preventive medication an adequate trial at a tolerated dose and reassess acute-medication frequency.

Algorithm

1. Confirm that the presentation is consistent with Chronic Migraine — Preventive Therapies & CGRP and identify immediately life-threatening alternatives or complications.
2. Obtain a focused history and examination that define severity, mechanism, relevant comorbidity, prior treatment, and baseline function.
3. Use targeted evaluation such as Headache diary, Neurologic examination, and other tests only when they can change management.
4. Classify the patient into a treatment pathway based on stability, disease/procedure subtype, organ function, and the presence or absence of escalation findings.
5. Begin the first-line intervention described for Chronic Migraine — Preventive Therapies & CGRP, using the least complex safe regimen that directly treats the mechanism.
6. Reassess symptoms, vital signs, examination, laboratory or imaging response, and treatment toxicity after the first clinically meaningful interval.
7. Stop routine progression and escalate care for thunderclap headache, meningismus, fever, papilledema, focal deficit, seizure, or altered mental status, new headache in pregnancy/postpartum, cancer, immunocompromise, or age over 50 with concerning features, or progressive pattern change or failure to improve despite appropriate migraine therapy where the diagnosis may be wrong.
8. At discharge or transition, document the final diagnosis, remaining uncertainty, medication/procedure plan, follow-up timing, prevention strategy, and explicit return precautions.

Clinical Synopsis & Reasoning

Chronic migraine is defined by headache on at least 15 days per month for more than three months, with migraine features on at least eight days per month. The diagnosis is clinical and should distinguish migraine from medication-overuse headache, new daily persistent headache, secondary causes, and other primary headache syndromes.

Use a headache diary to document frequency, migraine days, acute-medication use, disability, menstrual relationship, sleep, caffeine, triggers, and response to therapy. Screen for red flags such as thunderclap onset, new focal deficits, papilledema, pregnancy/postpartum risk, cancer/immunocompromise, fever, major pattern change, or new headache after age 50. Neuroimaging is not routinely required for a stable typical migraine phenotype with normal examination.

The practical diagnostic task is to decide what must be established immediately, what can be clarified after stabilization, and which finding would change the working diagnosis. Useful evaluation elements include Headache diary, Neurologic examination, MRI brain when indicated, Pregnancy/inflammatory/other targeted tests. Each test should answer a defined question rather than be ordered reflexively. Serial examination is especially important when early results can be normal or when treatment itself changes the physiology being measured.

Neurologic disorders often require careful attention to tempo, distribution, and positive examination findings because the same symptom can arise from very different anatomic mechanisms. For Chronic Migraine — Preventive Therapies & CGRP, the clinician should explicitly separate expected findings from escalation findings such as thunderclap headache, meningismus, fever, papilledema, focal deficit, seizure, or altered mental status, new headache in pregnancy/postpartum, cancer, immunocompromise, or age over 50 with concerning features, or progressive pattern change or failure to improve despite appropriate migraine therapy where the diagnosis may be wrong.

Treatment Strategy & Disposition

Offer preventive therapy when attacks are frequent or disabling. Options include CGRP-targeted monoclonal antibodies, preventive gepants, onabotulinumtoxinA for chronic migraine, topiramate, selected beta blockers, candesartan, and other patient-specific agents. Acute treatment can include NSAIDs, acetaminophen, triptans, gepants, or ditans according to vascular risk and prior response. Address medication overuse by limiting frequent acute-agent exposure and pairing withdrawal with effective prevention. Sleep regularity, exercise, hydration, meals, stress management, and behavioral therapy can reduce burden.

Track monthly migraine days and disability rather than asking only whether headaches are 'better.' Give a preventive medication an adequate trial at a tolerated dose and reassess acute-medication frequency.

Treatment should be reassessed after the first meaningful intervention rather than allowed to continue automatically. Relevant medications or therapeutic agents in this topic include CGRP monoclonal antibody, Preventive gepant, OnabotulinumtoxinA, Topiramate. Their usefulness depends on the indication, patient physiology, and contraindications shown in the sections below. If the response is poorer than expected, revisit the diagnosis, treatment delivery, adherence or access, procedure success when relevant, and the possibility of a complication.

Emergency red flags should be separated from chronic disability management: stabilization and exclusion of time-sensitive structural disease come first, followed by mechanism-specific treatment and rehabilitation. Functional outcomes, cognition, mobility, sleep, mood, and caregiver burden are important longitudinal endpoints in addition to examination findings.

Epidemiology / Risk Factors

• Chronic Migraine — Preventive Therapies & CGRP is a neurologic topic where tempo and examination pattern help distinguish common disease from time-sensitive mimics.
• Disability can persist even after the acute mechanism is treated, making rehabilitation, symptom management, and functional follow-up important parts of care.
• Delayed diagnosis is most harmful when a rapidly progressive, structural, vascular, infectious, or respiratory-threatening process is mistaken for a routine chronic syndrome.

Investigations

Preventive-Therapy Selection

Pharmacology

Prognosis / Complications

• Outcome in Chronic Migraine — Preventive Therapies & CGRP depends on baseline severity, underlying mechanism, comorbidity, speed of appropriate treatment, and whether major complications develop.
• Patients who respond as expected still need follow-up focused on recurrence prevention, treatment adverse effects, and restoration of function or physiologic stability.
• The appearance of thunderclap headache, meningismus, fever, papilledema, focal deficit, seizure, or altered mental status or new headache in pregnancy/postpartum, cancer, immunocompromise, or age over 50 with concerning features changes prognosis and should prompt a higher-acuity reassessment rather than routine outpatient progression.
• A durable plan is one that the patient can follow outside the clinical setting and that includes clear thresholds for returning to care.

Patient Education / Counseling

• Explain the diagnosis of Chronic Migraine — Preventive Therapies & CGRP in plain language, including what is known, what remains uncertain, and what the immediate treatment is intended to accomplish.
• Review how the patient should take or use the recommended therapy and what common adverse effects or practical barriers to expect.
• Explain that worsening symptoms are not always a normal part of recovery and give specific return precautions for thunderclap headache, meningismus, fever, papilledema, focal deficit, seizure, or altered mental status.
• Also seek prompt care for new headache in pregnancy/postpartum, cancer, immunocompromise, or age over 50 with concerning features or progressive pattern change or failure to improve despite appropriate migraine therapy where the diagnosis may be wrong.
• Discuss prevention or risk reduction relevant to the condition, including medication adherence, follow-up testing, rehabilitation, vaccination, sexual/partner management, or lifestyle factors as appropriate.
• Use teach-back at discharge so the patient or caregiver can state the treatment plan, follow-up timing, and reasons to return.

Notes

The main practical error in Chronic Migraine — Preventive Therapies & CGRP is to reduce the topic to a memorized list without linking each action to a clinical purpose. A safer approach identifies the decision point, chooses the test or intervention that changes that decision, and then reassesses whether the patient is moving in the expected direction. Findings such as thunderclap headache, meningismus, fever, papilledema, focal deficit, seizure, or altered mental status, new headache in pregnancy/postpartum, cancer, immunocompromise, or age over 50 with concerning features, and progressive pattern change or failure to improve despite appropriate migraine therapy where the diagnosis may be wrong should move the patient out of a routine pathway and into higher-acuity diagnostic or specialty assessment.

Documentation should make the reasoning reproducible. Record the baseline state, the key evidence supporting the diagnosis, major alternatives that were addressed, treatment actually delivered, response, and the follow-up responsibility. This is particularly important when multiple clinicians will share care or when a procedure, high-risk medication, evolving laboratory abnormality, or time-sensitive infection/vascular syndrome is involved. Once the patient is stable, the remaining work is prevention: address modifiable risk, treatment access, adherence, functional recovery, and the specific complication most likely to cause return to care.

References

1. American Headache Society - Migraine Treatment Guidance — Link
2. American Academy of Neurology - Clinical Practice Guidelines — Link
3. American Heart Association/American Stroke Association - Guidelines — Link